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result from unilateral peripheral dysfunction of the 
vestibular system or from the vestibular portion 
of the eighth brain nerve3,4, usually with unknown 
etiology5. 
The peripheral vestibular system is located in the 
inner ear and its primary function is to assist in the 
maintenance of postural balance. Balance can be 
defined as the ability to maintain a stable position of 
the body based on the location of mass center and 
gravity during static and dynamic positions, such as 
gait patterns6,7.  It is a complex process, involving 
the reception and integration of sensory stimuli 
(vestibular, visual and proprioceptive), in harmony 
with the central nervous system (CNS) and the 
  INTRODUCTION
Dizziness, vertigo and postural instability are 
frequent symptoms in vestibular disorders and affect 
not only functional capacity, but also individuals’ 
health-related quality of life (HRQoL) of both 
genders and different age range1,2. These symptoms 
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no statistically differences were observed concerning dizziness intensity (p=0.74) and health-related 
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study, a worse balance in different balance tasks was observed at the medicated group (ANCOVA, 
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approaches according to the current symptom of 
each individual18,20. In such case, the inclusion of 
quantitative measure, especially regarding postural 
balance, considered one of the main factors of falls 
among the elderly, becomes necessary to better 
clinical decision making.
The aim of this study was to evaluate the 
influence of anti-vertigo drugs treatment on health 
related quality of life and postural balance in older 
adults with dizziness complaints. 
  METHODS
This research is a descriptive, comparative 
cross-sectional study, with a quantitative 
approach, developed in the premises of a Physical 
Therapy Clinic of a higher education institution in 
Londrina-PR, from March 2012 to November 2013. 
The study was approved by the Ethics in Research 
Committee (Protocol no. 177.276/12) and all partici-
pants signed a written informed consent.
A convenience sample of individuals with 
complaints of dizziness was selected for the study, 
sent from different medical services in Londrina 
and region. Individuals were selected based on 
the following eligibility criteria described below: a) 
inclusion criteria - individuals of both genders, over 
18 years old, with chronic vestibular dysfunction 
characterized by complaints of dizziness and / or 
balance disorders and / or other nonspecific feelings 
of dizziness which have been present for at least 
three months, forwarded by a doctor, with higher 
scores or equal to one point on the Visual Analogue 
Scale (VAS) Dizziness and / or bigger or equal to 16 
points in the Dizziness Handicap Inventory (DHI). 
b) Exclusion criteria - individuals with visual and / 
or severe hearing  impairment (detected during 
air and bone tonal threshold search), inability to 
understand and meet the simple verbal commands 
and / or inability to adopt the requested positions, 
due to orthopedic disorders and / or injuries of the 
nervous system that resulted in motor deficit and / 
or additional sensory, and / or peripheral vestibular, 
such as the benign paroxysmal positional vertigo 
(BPPV), identified from the patients records and 
showed the presence of positional nystagmus  after 
Dix-Hallpike maneuver.
The study included 51 patients with chronic 
vestibular dysfunction, aged 20 to 83 years old. As 
for their current occupation, 14 (27.4%) were retired, 
13 (25.6%) managed household activities, seven 
(13.7%) were teachers. The remaining functional 
and clinical data are shown in Table 1.
musculoskeletal, for the planning and execution of 
body movements3,7.
It is estimated that vestibular symptoms affect 
5 to 10% of the population and the most common 
symptom appears after 65 years of age8. In adults, 
the prevalence is of 5% and the incidence of 1.4%, 
rates increase with the aging process and can be two 
to three times more frequent in woman9,10. Vestibular 
dysfunctions are present in 49.4% of seniors - 60 to 
69 years old, rising to 84.8% in people over 80 years 
old11.
The intensity and duration of clinical manifes-
tations that follow vestibular disorders often 
compromise social activities, family relations and 
labor causing physical, financial and psycho-
logical limitations, such as loss of self-confidence, 
depression, as well as giving rise to decreased 
concentration and physical performance12. In 
absolute figures, there is a considerable portion of 
the population predisposed to functional limitations 
arising from vestibular dysfunction, which leads 
to lower HRQoL indexes9,11. It is noteworthy that 
postural control is also damaged in individuals with 
vestibular disorders13,14.
Among most common treatment options for 
vestibular symptoms are drug treatment, reposi-
tioning maneuvers and vestibular rehabilitation. 
Regardless of the method applied, the goal is to 
control symptoms, reduce functional deficits and 
improve HRQoL of patients2. The pharmacological 
treatment with anti-vertigo drugs is the main 
approach for vestibular disorders amongst calcium 
channel blockers, anti-histamine drugs, anti-
dopaminergic drugs and / or benzodiazepines4,14.
On the other hand, due to high prevalence of 
dizziness complaints  from patients, the appropriate 
course of action would be forwarding the patient  for 
otorhinolaryngology care15,16, once it is known that 
anti-vertigo drugs should be carefully used and for 
the shortest amount of time as possible4,17.
Most importantly, the use of a single therapy 
mode may not be enough to complete resolution 
of vestibular complaints, as the pharmacological 
treatment can only provide temporary symptoms 
relief, but not the central compensation from the 
CNS-mediated mechanisms of neuroplasticity18,19 .
To date no study evaluating the clinical-functional 
impact of the use of anti-vertigo drugs on HRQoL 
and postural balance of adults of different age range. 
Moreover, the influence of the treatment duration 
with anti-vertigo drugs’ on the same variables is 
not known. It is worth mentioning the limitations 
in the diagnosing criteria by clinical research and 
especially the methodological biases and qualitative 
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Table 1 – Clinical data of the sample (n= 51)
Variables Categorias
Absolute 
Frequency
(n)
Relative 
Frequency
(%)
Gender Female 43 84.3%
Male 08 15.7%
Age range 20 – 40 years old 09 17.6%
41 – 60 years old 20 39.3%
> 60 years old or 22 43.1%
Symptoms’ Period < 1 year 15 29.4%
1- 10 years 25 49.0%
> 10 years 11 21.6%
Main Complaint Dizziness 32 62.7%
Dizziness and Tinnitus 11 21.6%
Dizziness and Heavy head 08 15.7%
Period of Dizziness Anytime 26 51.0%
Morning/Afternoon 17 33.3%
noite/madrugada 08 15.7%
Frequency of Dizziness Daily 27 52.9%
Weekly 11 21.6%
Monthlyl/Sporadic 13 25.5%
Dizziness’ duration Seconds/Minutes 21 41.2%
Hours/Days 30 58.8%
Dizziness’ characteristics Unbalance and Vertigo 16 31.4%
Vertigo 12 23.5%
Unbalance 19 37.3%
Unbalance and Obscured vision 04 7,8%
Associated symptoms Yes 49 96.1%
no 02 3.9%
Initially, patients with complaints of dizziness 
were evaluated in the institution’s Speech Therapy 
department for a hearing diagnostic assessment, 
which consisted of audiological anamnesis and 
pure tone audiometry. Afterwards, participants were 
evaluated by performing the diagnostic Dix-Hallpike 
maneuver in order to rule out recurrent symptoms 
due to BPPV. When the result was positive, the 
individual was treated through Epley, Semont or 
Brandt-Daroff maneuvers, according to the type 
of positional nystagmus on Dix-Hallpike by a 
specialized speech therapist. However, when the 
result of the diagnostic Dix-Hallpike was negative, 
the individual was referred to the physiotherapy 
department, and a  physiotherapy assessment 
was conducted as described below: data collection 
was performed by a specialist physiotherapist, 
using a protocol which consisted of the following 
assessment tools: a) participant identification form, 
with personal data, anamnesis, additional otoneu-
rological exams, medical history, use and treatment 
duration with anti-vertigo drugs, use of other medica-
tions and major complaints; b) evaluation form of 
vertigo symptoms, assessed through an interview, 
in order to find out about the following variables: 
clinical course of time (over one year), dizziness 
features, dizziness duration, frequency of dizziness 
and associated neurovegetative symptoms19,20. c) 
Dizziness Handicap Inventory Questionnaire (DHI) 
in order to evaluate the effects caused by dizziness 
on HRQoL. Used in many countries, this question-
naire was translated and adapted to the country’s 
cultural background to use with the Brazilian 
population in 2007.
It consists of 25 questions that analyze the 
occurrence of damage on the physical aspects 
(seven questions), nine functional questions and 
nine emotional questions about daily activities of 
the individuals assessed. For each question, there 
are three possible answers: “yes” (four points), 
“sometimes” (two points) and “No” (zero). The 
maximum possible score is 100 points, and the 
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To meet study objectives, participants were 
divided into two groups: 1) medicated Group (MG), 
formed by subjects undertaking anti-vertigo drugs; 
2) non-medicated group (NG), formed by subjects 
who did not use anti-vertigo medication. Anti-vertigo 
drugs used were: Betahistine dihydrochloride (8, 16 
or 24 mg), dimenhydrinate (100 mg), Flunarizine (10 
mg) and Ginkgobiloba extract (EGb 761) (40 mg). 
Data were descriptively and analytically 
analyzed, in the Statistical Package for Social 
Sciences (SPSS) program, version 18.0 (Serial 
number: 180012). Categorical variables related 
to dizziness characteristics were presented by 
absolute and relative frequencies. To investigate the 
association between these variables and the use of 
anti-vertigo drugs, the Chi Square test was used.
In order to verify the data normality of numerical 
variables of the study, the Shapiro-Wilk test was 
used. For comparison between the GM and GN 
groups, we used the Student t test for independent 
samples, as the normality assumption was granted 
for groups. Finally, the ANCOVA test was performed 
to compare groups in order to reduce the error 
variance and adjust the average covariables “time 
of use of anti-vertigo medication” for all subjects in 
a fixed amount. A confidence interval of 95% and 
a significance level of 5% (p <0.05) was set for all 
tests.
  RESULTS
Health-Related Quality of Life and dizziness 
intensity
The results from the DHI questionnaire analysis 
showed that vestibular symptoms caused negative 
impact on HRQoL of the participants, with a 
minimum of 16 and maximum of 96 points (Table 
2). According to the standard stratification by Yorke 
et al.21, 19 (37.2%) presented mild dysfunction, 13 
(25.6%) had moderate impairment and 19 (37.2%) 
serious dysfunction. Apparently, the distribution of 
total scores and dimensions were similar in both 
groups.
higher the value, the worse the perception of the 
individual’s HRQoL. The rating was established by 
dysfunction established by Yorke et al.21 as follows: 
mild (16 to 34 points), moderate impairment (36 to 
52 points) and severe impairment (over 54 points); 
c) Dizziness Visual Analog Scale (VAS), indicating 
the intensity of vertigo symptoms, that varies on 
a numerical scale from zero to ten, where zero 
indicates the absence of dizziness and ten, the 
worst dizziness intensity19.
This tool consists of a graphic-visual way to 
determine by self-report the intensity of dizziness 
during the evaluation; d) stabilometry to assess 
postural balance - the participants were evaluated 
on a force platform called BIOMEC400 (EMG 
System - Brazil, SP Ltda.), with data sampled at 100 
Hz22. Center of pressure variables were used (COP 
in cm2) and average speed of oscillation COP (VEL 
in cm / s) in both movement directions: anterior-
posterior (A/P) and medio-lateral (M/L). Participants 
were evaluated in the standing position, barefoot, 
loose and relaxed upper limbs beside the body, with 
the head positioned horizontally at ground level, 
and eyes directed to a fixed target on the wall, at 
the same eye level, at a distance of 2.5 meters (for 
tests with eyes open) 22. A protocol standardized by 
researchers was followed in four different conditions 
described below: 1) bipedal support with aligned 
feet with eyes open (BEO); 2) bipedal support, 
aligned feet with head rotation to the right and to the 
left, following audible feedback, using a metronome 
(BHR); 3) bipedal support in the position of semi-
Tanden (right foot forward to the left foot or the other 
way around, according to participant’s preference, 
with a slight space between feet and eyes open 
(STEO); and 4) eyes closed (STEC).
 In each position, the patient should remain on 
the force platform for 30 seconds. Two samples 
were taken for testing, with an interval of 30 seconds 
between them. The order of positions was achieved 
through simple drawing lots made by the individual 
himself, before the tests began. 
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Table 2 – Clinical and functional data, Dizziness Handicap Inventory (DHI) global and domains and 
Dizziness Visual Analogue Scale for global sample, for the medicated (MG) and non-medicated (NG) 
groups
Variables Total (n=51)Mean ± SD
MG (n= 25)
Mean ± SD
NG (n= 26)
Mean ± SD
p
(Unpaired t 
Test )
p
(Ancova)
Age (years) 56.1±14.4 54.3±12.5 57.7±15.8 0.32 _
Symptoms’ duration 
(years) 8.1±11.26 10.1±12.9 6.4±9.49 0.19 _
DHI total 47.4±22.4 46.6±23.4 48.1±21.9 0.79 0.39
DHI – Physical 
Aspects 17.2±6.4 16.6±6.9 17.7±5.9 0.89 0.33
DHI – Functional 
Aspects 17.9±9.6 17.4±9.7 18.3±9.6 0.86 0.40
DHI – 12.5±8.9 12.6±9.1 12.3±8.8 0.63 0.52
Dizziness Visual 
Analogue Scale 4.6±2.8 4.8±2.9 4.4±2.7 0.74 0.41
Notes: DHI – Dizziness Handicap Inventory; MG –  Medicated Group; NG – Non-medicated Group; SD – Standard Deviation.
Dizziness EVA revealed that on the assessment 
day, the intensity of dizziness was moderate for 
most participants – the values: minimum (zero) and 
maximum (ten) were reported (Table 2). However, 
even when the score on this scale was zero, which 
denotes the absence of symptoms, the participant 
was included in the study to present scores greater 
than 16 points in DHI.
Postural Balance
In stabilometry, the permanence time was 30 
seconds in all tests for 47 (92.2%) participants. Only 
four participants (7.8%) failed to complete the total 
time, especially in STEC and BHR tests, due to 
discomfort caused by the presence of symptoms at 
the time of testing. For those ones, the total perma-
nence time was taken into consideration when 
processing the data (Table 3).
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p = <0.001), after accounting for the effect of anti-
vertigo drugs usage time as a covariate (table 3).
  DISCUSSION
There was a higher proportion of female subjects 
(84.3%) who reported dizziness complaints. 
According to Neuhauser and Lempert9, dizziness 
is more frequent in women, with a ratio of 2:1, due 
to the association of vestibular disease, hormone 
and metabolic disorders and also women’s bigger 
concern to seek medical advice in relation to men.
HRQoL proved to be impaired for all participants, 
with a total score greater than 16 points at DHI. 
According to Yorke et al.21, this value indicates that 
dizziness has a negative impact on the daily life of 
individuals -scores higher than 10 points demon-
strate the need for an evaluation of dysfunction 
patients by an expert.
The scores of the total DHI and its three areas 
were similar to those found in other baseline studies, 
such as Santos et al.18, Hansson and Magnusson23, 
Bayat et al.24, Giray et al.25, Patatas, Ganança 
and Ganança26, Nishino, Granato and Campos27, 
Morettin, Mariotto and Costa Filho28 and Albera et 
al.29. It should be noted here that in studies where 
some form of treatment to minimize the vestibular 
symptoms was used, there was an improvement 
Comparison of clinical and functional variables 
concerning drug treatment, using the t test for 
independent samples
In the comparison between the GM and GN 
groups, there was no statistically significant 
difference in the DHI, dizziness VAS and the param-
eters analyzed in the four stabilometry tests. The 
significance values are described in Tables 2 and 3.
There was no association between the use of 
medication and categorical variables of the study: 
main complaint (p = 0.46), a period of crisis (p = 
0.42), frequency of crisis (p = 0.53), characterization 
of crisis (p = 0.24), duration of crisis (p = 0.68) and 
associated neurovegetative symptoms (p = 0.15).
Comparison of clinical and functional variables 
in relation to drug treatment using a covariate 
“time of use of anti-vertigo medication”
Considering the time of use of anti-vertigo drugs 
as a covariate, no statistically significant differences 
were found between the GM and GN groups on 
total DHI and physical, functional and emotional 
aspects as well as dizziness VAS (Table 2). On 
the other hand, the value of COP area in the three 
test conditions on force platform was significantly 
influenced by the use of anti-vertigo drug (BEO: p = 
0.004; BHR: p = 0.004; STEO: p = <0.001; STEC: 
Table 3 – Stabilometric parameters for total sample, for the medicated and non-medicated groups
Variables Total (n=51)Mean ± DP
MG (n= 25)
Mean ± DP
NG (n= 26)
Mean ± DP
p
(Unpaired t 
Test)
p
(Ancova)
BEO
COP area (cm2) 4.19±10.83 6.03±15.37 2.56±3.37 0.18 0.004*
VEL A/P (cm/s) 0.91±0.39 0.85±0.38 0.95±0.39 0.50 ɳ =0.12
VEL M/L (cm/s) 0.65±0.32 0.66±0.41 0.64±0.21 0.82
BHR
COP area (cm2) 3.63±2,57 4.41±3.10 2.94±1.77 0.77 0.004*
VEL A/P (cm/s) 1.20±0,37 1.18±0.30 1.22±0.43 0.47 ɳ =0.24
VEL M/L (cm/s) 0.86±0,26 0.90±0.25 0.83±0.26 0.62
STEO
COP area (cm2) 5.94±5.47 7.49±7.15 4.57±2.87 0.03* <0.001*
VEL A/P (cm/s) 1.59±1.42 1.63±0.64 1.55±0.50 0.69 ɳ =0.43
VEL M/L (cm/s) 1.42±0.50 1.40±0.44 1.44±0.55 0.78
STEC
COP area (cm2) 9.66±8.61 11.49±11.03 8.04±5.42 0.09 <0.001*
VEL A/P (cm/s) 2.29±0.98 2.27±0.94 2.31±1.04 0.86 ɳ =0.46
VEL M/L (cm/s) 2.17±0.90 2.07±0.77 2.26±1.01 0.40
Notes: MG – Medicated Group; NG – Non-medicated Group; COP area  – Center of Pressure Area; VEL – average Speed (Velocity); 
BEO – Bipedal support with Eyes Open; BHR – Bipedal support with Head Rotation; STEO – Semi-Tanden position with Eyes Open;
STEC – Semi-Tanden position with Eyes Closed; A/P – antero-posterior; M/L – medial-lateral; ɳ - effect size.
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considered abnormal when compared to subjects 
without complaints, showing that the vestibular 
dysfunction causes damage on postural control 
of individuals. Quitschal et al.31 also described the 
occurrence of impaired postural control in patients 
with unilateral vestibular hypofunction, and observed 
changes in weight distribution and synchronization 
of postural sway right / left fingers / heels, predis-
posing these individuals to an increased risk of falls .
In analyzing the stabilometric parameters 
of postural balance in BOE, BHR, STEO and 
STEC tests using the ANCOVA test, a statistically 
significant difference in favor of natural gas was 
found. That is, besides not providing symptom 
improvement for GM, the use of anti-vertigo drugs 
negatively affected the performance on postural 
balance tests. Analyzing the values of the effect in 
these tests, it is clear that the use of these drugs at 
this stage of the disease can promote deleterious 
effect on the long-term balance. According to Soto 
and Vega2, Singh and Singh17e Hain and Uddin33 it is 
important to know the mechanism of action of drugs 
used in the treatment of vestibular dysfunction so 
that the indication is beneficial.
Inadequate drug use may worsen the symptoms 
presented by the patients with such disorder. 
Still, the duration of use of anti-vertigo medication 
should be carefully evaluated, because if used for 
prolonged periods, it can slow the central clearing/ 
compensation that naturally occur by the SNC34. 
It is expected that the findings of this study may 
serve to clinical practice to alert health profes-
sionals, especially in primary care, in what refers to 
the appointment / prescription of anti-vertigo drugs, 
since the use of such drugs has not been associated 
with clinical improvement of patients with vestibular 
disorders in the chronic phase of the disease, and it 
may also predispose to the risk of side-effects when 
the use is prolonged and uncontrolled.
  CONCLUSION
Vestibular symptoms had a negative impact on 
HRQoL of patients with vestibular complaints who 
make use or not of anti-vertigo drugs. However 
postural balance has worsened in individuals under-
using such drugs.
in the HRQoL, with significant decreases in DHI 
questionnaire scores.
No statistically difference between the use or not 
of anti-vertigo drugs was observed with respect to the 
DHI (total and all domains) and EVA dizziness, when 
medication duration was assessed as a covariance 
with ANCOVA test. Therefore, one may assume 
that the pharmacological treatment with anti-vertigo 
drugs is not efficient for symptoms’ relief. Santos 
et al.18 reported in their study that the use of anti-
vertigo medication was not associated with worse 
or better HRQoL when compared to subjects who 
did not use them. The assumption of the authors is 
that in chronic phase of decompensated vestibular 
disorders, pharmacotherapy alone did not have 
much effect related to the aspects investigated. 
These results could be explained by the sample 
characteristics sample in this study, composed 
primarily by individuals in the chronic phase of the 
disease (disease duration greater than one year), 
who only then turned to a non-drug treatment for the 
problem. Similarly, Meldrum et al.30 suggest that the 
use of anti-vertigo medication should be done in the 
acute phase of vestibular dysfunction, and in chronic 
stages, the most suitable therapeutic approach is 
vestibular rehabilitation.
Still, poor performance in daily activities of 
patients with vestibular diseases can also occur by 
influences of impairment in postural control, since it 
may cause anxiety and fear, as well as difficulties in 
gait and orientation24. It is expected that individuals 
with complaints of dizziness show worse perfor-
mance in tests on the force platform, especially in 
situations of vestibular stress, such as the condi-
tions of closed eyes and unstable surface31. This 
occurs when one of the sensory components that 
interfere with postural control is faulty, for instance, 
the vestibular system, and as a result unpleasant 
reactions and symptoms may be present in everyday 
life32.
The absence of a control group without vestibular 
complaints hindered this analysis to this study, 
since no studies that used similar stabilometric 
assessment methods were found. Bastos, Lima and 
Oliveira5 made this comparison between individuals 
with and without vestibular complaints and found 
a different behavior between the two groups. The 
results obtained by individuals with complaints were 
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RESUMO
Objetivo: avaliar a influência do tratamento com fármacos antivertiginosos sobre a qualidade de vida 
e o equilíbrio postural de adultos e idosos com queixas de tontura.  Métodos: estudo transversal, 
com amostra de 51 indivíduos portadores de queixas de tontura, divididos em dois grupos, de acordo 
com o uso (grupo medicado, n=25) ou não (grupo não medicado, n=26) de fármacos antivertiginosos. 
Foram coletadas informações sobre: caracterização dos sintomas (ficha elaborada pelos pesquisa-
dores), autopercepção de qualidade de vida (Dizziness Handicap Inventory), intensidade de tontura 
(escala visual analógica de tontura) e equilíbrio postural (plataforma de força). Resultados: verificou-
-se intensidade moderada de tontura (Média: 4,6 ± 2,8) e impacto negativo das vestibulopatias sobre 
a qualidade de vida (Média: 47,3 ± 22,4) na amostra total. Quando comparados os dois grupos, 
não houve diferença estatisticamente significante na intensidade da tontura (p=0,74) ou qualidade 
de vida (p=0,79), e também, nos parâmetros da estabilometria, em quatro tarefas (teste t indepen-
dente, p>0,05). Contudo, após a inclusão do tempo de utilização de fármacos antivertiginosos como 
uma covariável do estudo, foi verificado pior desempenho nas diferentes tarefas da estabilometria no 
grupo medicado (ANCOVA, p<0,05). Conclusão: o uso de fármacos antivertiginosos não melhora 
a qualidade de vida de indivíduos com queixas de tontura e o equilíbrio postural esteve alterado no 
grupo medicado.
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